

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6340096

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
LINEAGE CELL THERAPEUTICS, INC.	07/10/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AGEX THERAPEUTICS, INC.
<b>Street Address:</b>	965 ATLANTIC AVENUE
<b>City:</b>	ALAMEDA
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94501
<b>PROPERTY NUMBERS Total: 11</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	61831421
Application Number:	14896664
Application Number:	62347075
Application Number:	16211690
PCT Number:	US1736452
Application Number:	61908621
Application Number:	62020343
Application Number:	14554019
Application Number:	62264311
Application Number:	15994302
PCT Number:	US1665366
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 449-6548
<b>Email:</b>	kkantorski@mccarter.com
<b>Correspondent Name:</b>	MCCARTER & ENGLISH, LLP
<b>Address Line 1:</b>	265 FRANKLIN STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110

<b>ATTORNEY DOCKET NUMBER:</b>	LINEAGE TO AGEX
<b>NAME OF SUBMITTER:</b>	WENDY THAI
<b>SIGNATURE:</b>	/Wendy Thai/
<b>DATE SIGNED:</b>	10/07/2020

**Total Attachments: 8**

source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page  
source=Lineage\_to\_AgeX\_Assignment\_(BIOT-065\_BIOT-075\_BIOT-067\_BIOT-073;\_131761-624\_055\_625\_626)#page

**ASSIGNMENT - WORLDWIDE**

This ASSIGNMENT is made effective as of August 17, 2017 by and between:

**LINEAGE CELL THERAPEUTICS, INC. [formerly known as BioTime, Inc.]**, having its principal place of business at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008, United States of America (hereinafter referred to as "ASSIGNOR"); and

**AGEX THERAPEUTICS, INC.**, having its principal place of business at 965 Atlantic Avenue, Alameda, CA 94501, United States of America (hereinafter referred to as "ASSIGNEE").

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto ASSIGNEE, its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to: (a) the inventions set forth in the Patent Applications listed in the attached **SCHEDULE A**; (b) the Patent Applications and Letters Patent listed in **SCHEDULE A**; (c) all Letters Patent which may issue from said Patent Applications in the United States and countries foreign thereto; (d) all divisions, continuations, reissues, and extensions of said Patent Applications and Letters Patent; and (e) the right to claim for any of said Patent Applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE, its successors and assigns to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE, its successors and assigns or otherwise as ASSIGNEE, its successors and assigns may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks of the United States and the corresponding authorities in other countries to issue said Letters Patent to ASSIGNEE, its successors and assigns as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, any facts and information reasonably known or available to ASSIGNOR respecting said invention or inventions that may be related to interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes

or other legal, judicial, or administrative proceedings, when reasonably requested by ASSIGNEE, its successors and assigns; (b) to testify in person or by affidavit if required in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, its successors and assigns, all lawful papers available or made available to ASSIGNOR including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto when reasonably requested by ASSIGNEE, its successors and assigns.

AND ASSIGNOR HEREBY CONVEYS TO ASSIGNEE all rights arising under or pursuant to any and all United States and foreign laws and international agreements, treaties or laws relating to the protection of industrial property for such Patent Applications and Letters Patent, including but not limited to any cause(s) of action and damages accruing prior to this ASSIGNMENT.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNEE expressly accepts this assignment and transfer of patent rights made on its behalf and is now the owner of the Patent Applications listed in the attached Schedule A and the inventions set forth therein, with all rights, titles, and interests deriving from them.


ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office and the corresponding authorities in other countries for recordation of this Assignment.

This ASSIGNMENT may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, and may be executed through the use of facsimiles or .pdf documents.

IN WITNESS WHEREOF, ASSIGNOR intending to be legally bound has caused this ASSIGNMENT to be executed by its duly authorized representative this 17th day of June, 2020.

**ASSIGNOR:**

LINEAGE CELL THERAPEUTICS, INC., formerly known as BioTime, Inc.

By:  \_\_\_\_\_  
DocuSigned by:  
SE5B780EC22D471...

Name: Chase C. Leavitt

Title: General Counsel and Corporate Secretary

IN WITNESS WHEREOF, ASSIGNEE intending to be legally bound has caused this ASSIGNMENT to be executed by its duly authorized representative this 10th day of July, 2020.

**ASSIGNEE:**

AGEX THERAPEUTICS, INC.

By:  \_\_\_\_\_  
DocuSigned by:  
Michael West  
4E5807DD9F224AF...

Name: Michael D. West

Title: Chief Executive Officer

**SCHEDULE A**

Client Reference No.	Title	Country	Application No.	Filing Date	Status or Patent No. (Grant Date)	Attorney Docket No.
BIOT-065PRV	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	US	61/831,421	6/5/2013	Completed	131761-62401
BIOT-065US	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	US	14/896,664	12/7/2015	Published	131761-62404
BIOT-065PCT	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	WO	PCT/US2014/040601	6/3/2014	Completed	131761-62420
BIOT-065AU	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	AU	2014275130	1/4/2016	2014275130 (Granted 1/2/2020)	131761-62424
BIOT-065CA	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	CA	2914615	12/03/2015	Pending	131761-62426
BIOT-065CN	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	CN	201480044267.9	2/4/2016	Published	131761-62428
BIOT-065EP	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	EP	14807869.4	12/21/2015	Allowed	131761-62435

BIOT-065JP	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	JP	2016-518393	12/3/2015	6529486 (Granted 5/24/2019)	131761-62443
BIOT-065AUDIV1	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	AU	2019279909	12/9/2019	Pending	131761-62476
BIOT-065JPDIV1	COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES	JP	2019-091651	5/14/2019	Pending	131761-62477
BIOT-075PRV	IMPROVED METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	US	62/347,075	6/7/2016	Complete	131761-05501
BIOT-075US	METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	US	16/211,690	12/6/2018	Published	131761-05502
BIOT-075PCT	IMPROVED METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	WO	PCT/US2017/036452	6/7/2017	Completed	131761-05520
BIOT-075AU	IMPROVED METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	AU	2017278931	12/3/2018	Pending	131761-05524



BIOT-075CA	IMPROVED METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	CA	3026874	12/6/2018	Pending	131761-05526
BIOT-075EP	IMPROVED METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	EP	17810984.9	12/17/2018	Published	131761-05535
BIOT-075JP	IMPROVED METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES	JP	2018-563796	12/6/2018	Published	131761-05543
BIOT-067PRV	IMPROVED METHODS FOR GENERATING PLURIPOTENT STEM CELL DERIVED BROWN FAT CELLS	US	61/908,621	11/25/2013	Completed	131761-62501
BIOT-067PRV2	IMPROVED METHODS FOR GENERATING PLURIPOTENT STEM CELL DERIVED BROWN FAT CELLS	US	62/020,343	11/25/2013	Completed	131761-62502
BIOT-067	METHODS FOR GENERATING PLURIPOTENT STEM CELL- DERIVED BROWN FAT CELLS	US	14/554,019	11/25/2014	Published	131761-62503
BIOT-073PRV	METHODS FOR THE RE- DERIVATION OF DIVERSE PLURIPOTENT STEM CELL- DERIVED BROWN FAT CELLS	US	62/264,311	12/7/2015	Completed	131761-62601

BIOT-073	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	US	15/994,302	5/31/2018	Published	131761-62602
BIOT-073PCT	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	WO	PCT/US2016/065366	12/7/2016	Completed	131761-62620
BIOT-073AU	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	AU	2016366158	6/14/2018	Pending	131761-62624
BIOT-073CA	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	CA	3007733	6/6/2018	Pending	131761-62626
BIOT-073CN	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	CN	201680079866.3	7/24/2018	Published	131761-62628
BIOT-073EP	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	EP	16873761.7	6/28/2018	Published	131761-62635
BIOT-073IN	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	IN	201847024728	7/3/2018	Published	131761-62640
BIOT-073JP	METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLS	JP	2018-549142	6/5/2018	Published	131761-62643